Skip to main content
. 2021 Dec 15;11(6):443–475.

Figure 8.

Figure 8

177Lu-PSMA-617 therapy in a 65-year-old man with mCRPC. (A) The baseline pre-therapy diagnostic 68Ga-PSMA-11 PET/CT showed PSMA-avid extensive skeletal metastases, (B) Posterior whole body scintigraphy (WBS) 24 h after administration of first cycle of 177Lu-PSMA-617, (C) Posterior WBS 24 h after administration of second cycle of 177Lu-PSMA-617 showed remarkable reduction in uptake, (D) Posterior WBS 24 h after administration of third cycle of 177Lu-PSMA-617 did not show any abnormal uptake, (E) After three cycles of therapy, the follow-up diagnostic 68Ga-PSMA-11 PET/CT scan showed near complete metabolic response with resolution of the PSMA-avid metastases. Adapted from Ref [120].